enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate

Phase 2Recruiting
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer

Trial Timeline

Dec 22, 2016 → Jul 31, 2029

About enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate

enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate is a phase 2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02960022. Target conditions include Prostate Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02960022Phase 2Recruiting

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
PemetrexedEli LillyPhase 2
52
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
77
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
65
eFT508eFFECTOR TherapeuticsPhase 2
44
EnhertuDaiichi SankyoPhase 2
52
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
PLX3397Daiichi SankyoPhase 2
52
Valemetostat + DarolutamideDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
33
degarelix + GoserelinAstellas PharmaPhase 3
77
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
23
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
52
YM155Astellas PharmaPhase 2
52